Trevena Inc (TRVN)
$1.47
Performance
- $1.13$1.93$1.47
23.13%
Downside
Day's Volatility :41.45%
Upside
23.83%
- $1.47$19.23$1.47
0.0%
Downside
52 Weeks Volatility :92.36%
Upside
92.36%
Returns
| Period | Trevena Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -72.78% | 0.0% |
6 Months | -85.31% | 0.0% |
1 Year | -89.68% | 0.0% |
3 Years | -99.8% | -20.8% |
Highlights
Market Capitalization | 2.1M |
Book Value | - $22.23 |
Earnings Per Share (EPS) | -56.5 |
PEG Ratio | 0.0 |
Wall Street Target Price | 100.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2000.92% |
Return On Assets TTM | -71.51% |
Return On Equity TTM | -1014.58% |
Revenue TTM | 443.0K |
Revenue Per Share TTM | 0.61 |
Quarterly Revenue Growth YOY | -89.2% |
Gross Profit TTM | -3.4M |
EBITDA | -35.0M |
Diluted Eps TTM | -56.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -31.19 |
EPS Estimate Next Year | -19.85 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.35 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 6702.72%
Technicals Summary
Sell
Neutral
Buy
Trevena Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Trevena Inc | -71.18% | -85.31% | -89.68% | -99.8% | -99.74% |
 Regeneron Pharmaceuticals, Inc. | -12.19% | 6.5% | 20.85% | 84.03% | 245.65% |
 Novo Nordisk A/s | -11.15% | -6.13% | 27.31% | 138.21% | 354.53% |
 Alnylam Pharmaceuticals, Inc. | 5.38% | 73.95% | 61.12% | 32.59% | 252.19% |
 Vertex Pharmaceuticals Incorporated | -2.58% | 13.46% | 29.21% | 155.56% | 172.0% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Trevena Inc | NA | NA | 0.0 | -31.19 | -10.15 | -0.72 | NA | -22.23 |
Regeneron Pharmaceuticals, Inc. | 26.37 | 26.37 | 1.36 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.54 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Trevena Inc | Buy | $3.9M | -99.74% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $109.8B | 245.65% | 26.37 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 354.53% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 252.19% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $115.8B | 172.0% | 32.84 | -4.74% |
Insights on Trevena Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 20.0K → 325.0K (in $), with an average increase of 93.9% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -8.01M → -4.89M (in $), with an average increase of 20.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 150.8%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 132.9%
Institutional Holdings
BlackRock Inc
0.64%Renaissance Technologies Corp
0.62%Geode Capital Management, LLC
0.54%Vanguard Group Inc
0.34%Baader Bank INC
0.12%State Street Corp
0.12%
Company Information
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Organization | Trevena Inc |
Employees | 23 |
CEO | Ms. Carrie L. Bourdow |
Industry | Health Technology |
Discover More
Virios Therapeutics Inc
$1.47
-41.2%
Schwab International Dividend Equity Etf
$1.47
-41.2%
Allianzim Us Equity Buffer15 Uncapped Sep Etf
$1.47
-41.2%
Flexshares Quality Dividend
$1.47
-41.2%
Clene Inc
$1.47
-41.2%
Farmmi Inc
$1.47
-41.2%
Vitesse Energy Inc.
$1.47
-41.2%
Anfield Us Equity Sector Rotation Etf
$1.47
-41.2%
Graniteshares 2x Long Baba Daily Etf
$1.47
-41.2%